KR20220164473A - 생체외 감마 델타 t 세포 집단 - Google Patents

생체외 감마 델타 t 세포 집단 Download PDF

Info

Publication number
KR20220164473A
KR20220164473A KR1020227029501A KR20227029501A KR20220164473A KR 20220164473 A KR20220164473 A KR 20220164473A KR 1020227029501 A KR1020227029501 A KR 1020227029501A KR 20227029501 A KR20227029501 A KR 20227029501A KR 20220164473 A KR20220164473 A KR 20220164473A
Authority
KR
South Korea
Prior art keywords
seq
cells
antibody
optionally
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227029501A
Other languages
English (en)
Korean (ko)
Inventor
올리버 누스바우머
옥사나 폴리야코바
아드리안 헤이데이
피에르 반투루트
Original Assignee
감마델타 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 감마델타 테라퓨틱스 리미티드 filed Critical 감마델타 테라퓨틱스 리미티드
Publication of KR20220164473A publication Critical patent/KR20220164473A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020227029501A 2020-02-24 2021-02-24 생체외 감마 델타 t 세포 집단 Pending KR20220164473A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies
GB2002581.3 2020-02-24
PCT/GB2021/050460 WO2021171003A1 (en) 2020-02-24 2021-02-24 Ex vivo gamma delta t cell populations

Publications (1)

Publication Number Publication Date
KR20220164473A true KR20220164473A (ko) 2022-12-13

Family

ID=70108379

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227029501A Pending KR20220164473A (ko) 2020-02-24 2021-02-24 생체외 감마 델타 t 세포 집단
KR1020227033455A Pending KR20220145894A (ko) 2020-02-24 2021-02-24 신규 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227033455A Pending KR20220145894A (ko) 2020-02-24 2021-02-24 신규 항체

Country Status (17)

Country Link
US (2) US20230090901A1 (https=)
EP (3) EP4110387B1 (https=)
JP (2) JP2023516925A (https=)
KR (2) KR20220164473A (https=)
CN (2) CN115697401A (https=)
AU (2) AU2021228266A1 (https=)
BR (2) BR112022016894A2 (https=)
CA (2) CA3168973A1 (https=)
CL (1) CL2022002296A1 (https=)
CO (2) CO2022013542A2 (https=)
EC (1) ECSP22074030A (https=)
GB (1) GB202002581D0 (https=)
IL (2) IL295696A (https=)
MX (2) MX2022010239A (https=)
PE (1) PE20230438A1 (https=)
WO (2) WO2021171003A1 (https=)
ZA (1) ZA202209699B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
US11299708B2 (en) * 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用

Also Published As

Publication number Publication date
US20230090901A1 (en) 2023-03-23
EP4591882A2 (en) 2025-07-30
AU2021228266A1 (en) 2022-10-13
PE20230438A1 (es) 2023-03-08
WO2021171002A1 (en) 2021-09-02
CA3172340A1 (en) 2021-09-02
CA3168973A1 (en) 2021-09-02
ZA202209699B (en) 2024-12-18
EP4110387A1 (en) 2023-01-04
ECSP22074030A (es) 2022-10-31
EP4110387B1 (en) 2025-05-21
GB202002581D0 (en) 2020-04-08
KR20220145894A (ko) 2022-10-31
CO2022013633A2 (es) 2023-02-16
BR112022016894A2 (pt) 2023-04-04
BR112022016671A2 (pt) 2022-11-16
CN115697401A (zh) 2023-02-03
CN115461369A (zh) 2022-12-09
IL295852A (en) 2022-10-01
JP2023514437A (ja) 2023-04-05
US20230159638A1 (en) 2023-05-25
MX2022010239A (es) 2022-11-14
EP4110813A1 (en) 2023-01-04
CL2022002296A1 (es) 2023-03-31
JP2023516925A (ja) 2023-04-21
AU2021225390A1 (en) 2022-09-22
EP4591882A3 (en) 2025-10-15
IL295696A (en) 2022-10-01
CO2022013542A2 (es) 2022-10-11
MX2022010383A (es) 2022-09-05
WO2021171003A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CN113039205B (zh) 靶向cll1的抗体及其应用
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
JP7764364B2 (ja) エクスビボγδ Ｔ細胞集団
JP2026009903A (ja) 新規な抗ｔｃｒデルタ可変１抗体
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
KR20180132751A (ko) Bcma 결합 분자 및 그의 사용 방법
KR102439395B1 (ko) Ilt7 결합 분자 및 이의 사용 방법
KR20220164473A (ko) 생체외 감마 델타 t 세포 집단
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
HK40084452A (en) Novel antibodies
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
HK40130434A (en) Ex vivo gamma delta t cell populations
EA052465B1 (ru) Популяции гамма-дельта т-клеток ex vivo
HK40075692A (en) Novel anti-tcr delta variable 1 antibodies
WO2025031290A1 (zh) 抗ox40l抗体以及其用途
HK40086246B (en) Ex vivo gamma delta t cell populations
HK40086246A (en) Ex vivo gamma delta t cell populations
HK40047112B (en) Novel cancer immunotherapy antibody compositions
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902